Back

Synergically enhanced anti-tumor immunity of in vivo CAR by circRNA vaccine boosting

Wang, Y.; Lin, L.; Wang, X.; Li, J.; Yin, J.; Gao, F.; Liao, X.; Zhang, C.; Yin, Q.; Zhao, C.; Lin, J.; Xu, Y.; Qiu, M.; Luo, D.; Qu, L.

2024-07-07 immunology
10.1101/2024.07.05.600312 bioRxiv
Show abstract

Chimeric Antigen Receptor (CAR) T cell therapy has shown promise in treating hematologic malignancies. However, it is limited to individualized cell therapy and faces challenges, including high costs, extended preparation time, and limited efficacy against solid tumors. Here, we generated circular RNAs (circRNAs) encoding Chimeric Antigen Receptor (CAR) transmembrane proteins, referred to as circRNACAR, which mediated remarkable tumor killing in both T cells and macrophages. In addition, macrophages exhibited efficient phagocytosis of tumor cells and pro-inflammatory polarization induced by circRNACAR in vitro. We demonstrated that circRNACAR, delivered with immunocyte-tropic lipid nanoparticles (LNPs), significantly inhibited tumor growth, improved survival rates and induced a pro-inflammatory tumor microenvironment in mice. Importantly, the combination of circRNAAnti-HER2-CAR and circRNA-based cancer vaccines encoding the corresponding transmembrane HER2 antigen, termed circRNAHER2, exhibited synergistically enhanced anti-tumor activity. This proof-of-concept study demonstrated that the combination of circRNA-based in vivo CAR and vaccines, termed in vivo CAR-VAC, holds the potential to become an upgraded off-the-shelf immunotherapy.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 4%
27.1%
Similar papers in this journal
2
Cell Research
○ 51 papers in training set
Top 0.1%
6.9%
Similar papers in this journal
3
Cell Discovery
○ 57 papers in training set
Top 0.1%
5.6%
Similar papers in this journal
4
Science Advances
● 1243 papers in training set
Top 9%
3.5%
Similar papers in this journal
5
Cell
○ 431 papers in training set
Top 3%
3.3%
Similar papers in this journal
6
eLife
● 5828 papers in training set
Top 39%
2.7%
7
Signal Transduction and Targeted Therapy
○ 30 papers in training set
Top 0.2%
2.4%
50% of probability mass above
8
Nature Biomedical Engineering
○ 47 papers in training set
Top 0.5%
2.4%
9
Cell Reports
○ 1498 papers in training set
Top 15%
2.4%
10
Advanced Science
○ 286 papers in training set
Top 3%
2.4%
11
Protein & Cell
◐ 25 papers in training set
Top 0.2%
2.2%
12
Nature Immunology
○ 79 papers in training set
Top 1%
1.8%
13
Molecular Therapy
○ 81 papers in training set
Top 0.8%
1.8%
14
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 27%
1.7%
15
National Science Review
◐ 21 papers in training set
Top 0.1%
1.7%
16
Nature Chemical Biology
○ 119 papers in training set
Top 2%
1.5%
17
Science Translational Medicine
● 127 papers in training set
Top 2%
1.5%
18
Nature Biotechnology
○ 172 papers in training set
Top 3%
1.4%
19
Immunity
○ 67 papers in training set
Top 1%
1.2%
20
Nature
○ 645 papers in training set
Top 8%
1.2%
21
Cell Reports Medicine
○ 153 papers in training set
Top 3%
1.2%
22
ACS Nano
● 113 papers in training set
Top 2%
1.2%
23
Communications Biology
○ 993 papers in training set
Top 24%
1.1%
24
Science
● 477 papers in training set
Top 8%
1.0%
25
iScience
○ 1154 papers in training set
Top 30%
1.0%
26
Nature Medicine
○ 125 papers in training set
Top 3%
0.9%
27
Nature Nanotechnology
○ 32 papers in training set
Top 0.6%
0.9%
28
Nucleic Acids Research
◐ 1281 papers in training set
Top 14%
0.6%
29
Med
○ 39 papers in training set
Top 0.9%
0.6%
30
Science Bulletin
○ 21 papers in training set
Top 0.4%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.